Litcius/Paper detail

New progress in the treatment of diffuse midline glioma with H3K27M alteration

Zhi Yang, Liang Sun, Hai‐Bin Chen, Caixing Sun, Liang Xia

2024Heliyon10 citationsDOIOpen Access PDF

Abstract

Diffuse midline glioma with H3K27 M alteration is a primary malignant tumor located along the linear structure of the brain, predominantly manifesting in children and adolescents. The mortality rate is exceptionally high, with a mere 1 % 5-year survival rate for newly diagnosed patients. Beyond conventional surgery, radiotherapy, and chemotherapy, novel approaches are imperative to enhance patient prognosis. This article comprehensively reviews current innovative treatment modalities and provides updates on the latest research advancements in preclinical studies and clinical trials focusing on H3K27M-altered diffuse midline glioma. The goal is to contribute positively to clinical treatment strategies.

Topics & Concepts

GliomaMedicineRadiation therapyOverall survivalModalitiesChemotherapySurvival rateClinical trialTreatment modalityOncologyMedical physicsSurgeryInternal medicineCancer researchSocial scienceSociologyGlioma Diagnosis and TreatmentBrain Metastases and TreatmentNeuroblastoma Research and Treatments